Bioventus (NASDAQ:BVS) Reaches New 12-Month High – Here’s Why

Shares of Bioventus Inc. (NASDAQ:BVS) hit a new 52-week high during trading on Thursday . The company traded as high as $12.41 and last traded at $12.4190, with a volume of 35775 shares trading hands. The stock had previously closed at $11.97.

Wall Street Analyst Weigh In

BVS has been the topic of several research reports. Canaccord Genuity Group restated a “buy” rating and set a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bioventus in a research report on Tuesday, June 2nd. CJS Securities started coverage on shares of Bioventus in a report on Friday, March 27th. They set a “market outperform” rating and a $14.00 target price on the stock. Finally, Barrington Research reissued an “outperform” rating and set a $14.00 target price on shares of Bioventus in a report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $14.75.

Bioventus Stock Performance

The firm has a market capitalization of $1.04 billion, a P/E ratio of 30.52, a price-to-earnings-growth ratio of 1.47 and a beta of 0.65. The company has a 50-day moving average of $9.82 and a 200-day moving average of $9.08. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08.

Bioventus (NASDAQ:BVS) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. The firm had revenue of $132.09 million for the quarter. Bioventus had a return on equity of 29.97% and a net margin of 4.94%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, equities analysts anticipate that Bioventus Inc. will post 0.79 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

Several institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Bioventus by 19.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 162,412 shares of the company’s stock valued at $1,486,000 after purchasing an additional 26,103 shares during the last quarter. Legal & General Group Plc increased its position in shares of Bioventus by 100.9% during the second quarter. Legal & General Group Plc now owns 71,409 shares of the company’s stock worth $473,000 after buying an additional 35,873 shares during the period. Rhumbline Advisers increased its position in shares of Bioventus by 20.6% during the second quarter. Rhumbline Advisers now owns 65,093 shares of the company’s stock worth $431,000 after buying an additional 11,133 shares during the period. Finally, Marshall Wace LLP raised its stake in Bioventus by 32.5% during the second quarter. Marshall Wace LLP now owns 211,695 shares of the company’s stock worth $1,401,000 after buying an additional 51,951 shares during the last quarter. 62.94% of the stock is currently owned by institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.